| __timestamp | ADMA Biologics, Inc. | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9517014 | 15823000 |
| Thursday, January 1, 2015 | 7015946 | 17026000 |
| Friday, January 1, 2016 | 7688238 | 15941000 |
| Sunday, January 1, 2017 | 6229587 | 18938000 |
| Monday, January 1, 2018 | 3926120 | 58124000 |
| Tuesday, January 1, 2019 | 2343848 | 83837000 |
| Wednesday, January 1, 2020 | 5907013 | 35882000 |
| Friday, January 1, 2021 | 3646060 | 64542000 |
| Saturday, January 1, 2022 | 3613764 | 67995000 |
| Sunday, January 1, 2023 | 3300000 | 80118000 |
Cracking the code
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, ADMA Biologics, Inc. and CymaBay Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, CymaBay consistently outpaced ADMA, with R&D expenses peaking at approximately $80 million in 2023, a staggering 400% increase from 2014. In contrast, ADMA's R&D spending showed a downward trend, decreasing by about 65% over the same period. This divergence highlights CymaBay's aggressive pursuit of new therapeutic solutions, while ADMA appears to be adopting a more conservative approach. As the biotech industry continues to evolve, these strategic choices in R&D investment will likely shape the future trajectories of these companies.
Comparing Innovation Spending: Merck & Co., Inc. and ADMA Biologics, Inc.
R&D Spending Showdown: AstraZeneca PLC vs CymaBay Therapeutics, Inc.
Research and Development Investment: Gilead Sciences, Inc. vs CymaBay Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for argenx SE and ADMA Biologics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and ADMA Biologics, Inc.
R&D Insights: How Bio-Techne Corporation and ADMA Biologics, Inc. Allocate Funds
Research and Development Expenses Breakdown: Ionis Pharmaceuticals, Inc. vs ADMA Biologics, Inc.
Research and Development: Comparing Key Metrics for TG Therapeutics, Inc. and ADMA Biologics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for ADMA Biologics, Inc. and Iovance Biotherapeutics, Inc.
R&D Spending Showdown: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Research and Development: Comparing Key Metrics for ADMA Biologics, Inc. and Viridian Therapeutics, Inc.
R&D Insights: How CymaBay Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd. Allocate Funds